Holen Sie sich die Stockscreener-App
0.628
7.17%
0.042
Handel nachbörslich:
.63
0.002
+0.32%
Rein Therapeutics Inc Aktie (RNTX) Neueste Nachrichten
Rein Therapeutics Inc (RNTX-Q) Stock Price and News - The Globe and Mail
Rein Therapeutics (RNTX) Ticks Up 1.37% to $0.80 as Traders Eye ResistanceFibonacci Retracement - dars.gov.et
Rein Therapeutics at cantor global healthcare: ipf push gains traction By Investing.com - Investing.com South Africa
Rein Therapeutics at cantor global healthcare: ipf push gains traction By Investing.com - Investing.com Canada
Rein Therapeutics at cantor global healthcare: ipf push gains traction - Investing.com
Rein Therapeutics at cantor global healthcare: ipf push gains traction - Investing.com India
RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results - TradingView
We're Hopeful That Rein Therapeutics (NASDAQ:RNTX) Will Use Its Cash Wisely - simplywall.st
Rein Therapeutics Highlights LTI-03 Progress in IPF - TipRanks
Rein Therapeutics publishes LTI-03 presentation; Phase 1b biomarker signals and Phase 2 RENEW now enrolling - TradingView
Inhaled IPF drug from Rein Therapeutics (NASDAQ: RNTX) shows early safety data - Stock Titan
A study of an inhaled treatment for lung scarring will be presented Sept. 8 in Barcelona. - Stock Titan
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Rein Therapeutics to Present at Upcoming September Investor Conferences - Yahoo Finance
Here's Why You Should Add RNTX Stock to Your Portfolio Now - The Globe and Mail
Here's Why You Should Add RNTX Stock to Your Portfolio Now - Eastern Progress
Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price - The Globe and Mail
Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price - TipRanks
Rein Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - kalkine.ca
Rein (RNTX) Quarter in Focus: The Available Earnings Metric Delivers a Beat on the Day; Post-Report: Shares Move 0.88% Higher in the Current UpdateGuidance Accuracy Score - vinanet.vn
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Nigeria
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Australia
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Canada
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - The Manila Times
Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival - Stock Titan
Equities Analysts Set Expectations for RNTX FY2026 Earnings - MarketBeat
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Yahoo Finance
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - Kalkine
What is HC Wainwright's Estimate for RNTX FY2030 Earnings? - MarketBeat
RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com UK
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Tech Earnings Analysis - vinanet.vn
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Revenue Report - dars.gov.et
Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results - MarketBeat
Rein Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Rein Therapeutics (RNTX) Holds at $0.79 as Range-Bound Trading PersistsVWAP Bounce - vinanet.vn
Rein Therapeutics raises $44.3M to fund lung-disease drug trial - Dealroom
Rein Therapeutics Raises $44.3 Million in Public Offering - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Rein Therapeutics Surpasses 25% Enrollment in Phase 2 RENEW Trial of LTI-03 for IPF, Completes $57.5 Million Public Offering - Quiver Quantitative
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Press Release: Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary - TradingView
RNTX: Q2 net loss narrowed, liquidity strengthened, and Phase 2 LTI-03 trial remains on track - TradingView
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):